Related Experiment Videos
Beta-blockers and heart failure: meta-analysis of mortality trials
1European College of Pharmaceutical Medicine, Lyon, France. ajm.cleophas@wxs.nl
Background:
Four large double-blind placebo-controlled studies have been performed to address mortality as a primary endpoint in patients with heart failure treated with beta-blockers. Unfortunately, 2 of the studies were stopped in the interim stage, and so these trials may be somewhat underpowered for the estimation of the secondary endpoint, type of death. This endpoint is important, because if patients die for reasons other than progression of heart failure, e.g. arrhythmias, then alternative antiarrhythmic agents may serve equally well or better than beta-blockers and with fewer side effects.
Objectives And Methods:
We assessed hazard ratios of all-cause-deaths, sudden deaths, death due to progressive heart failure and serious adverse effects leading to discontinuation of double-blind treatment. Hazard ratio = risk of death in treatment group/risk of death in placebo group.
Results:
The pooled results showed a significant reduction in all-cause-deaths of 35% (p < 0.0001). The risk reduction of sudden death, reflecting the occurrence of fatal arrhythmias, similarly, showed a significant risk reduction of 37% (p < 0.0001). However, the risk reduction of death due to progression to heart failure was small (13%) and statistically non-significant, indicating that progression of heart failure, as estimated by numbers of deaths, was not beneficially influenced by the beta-blocker therapy. Finally, the risk of serious adverse effects leading to discontinuation of treatment with beta-blockers, was not significantly different from that for placebo.
Conclusions:
Beta-blockers do not reduce the risk of death due to progression of heart failure. The beneficial effect of beta-blockers is mainly due to a reduced risk of fatal arrhythmias. The risk of serious adverse effects of beta-blockers is not different from that of placebo and so there is little argument to withhold this treatment, even if it does not influence the progression of heart failure.
Insights
Beta-blockers significantly reduce all-cause and sudden cardiac deaths in heart failure patients, primarily by preventing fatal arrhythmias. They do not impact death from heart failure progression, but adverse effects are comparable to placebo.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Beta-blockers are used in heart failure patients, with mortality as a key endpoint.
- Previous studies may have been underpowered to analyze specific causes of death.
Purpose of the Study:
- To assess the impact of beta-blockers on all-cause mortality, sudden death, heart failure progression deaths, and adverse effects.
- To calculate hazard ratios for these outcomes.
Main Methods:
- Pooled analysis of four large double-blind placebo-controlled studies.
- Evaluation of hazard ratios for different death types and treatment discontinuation due to adverse events.
Main Results:
- Beta-blockers significantly reduced all-cause deaths by 35% (p < 0.0001) and sudden deaths by 37% (p < 0.0001).
- A small, non-significant 13% risk reduction was observed for death due to heart failure progression.
- Serious adverse effects leading to discontinuation were not significantly different between beta-blocker and placebo groups.
Conclusions:
- Beta-blockers are effective in reducing fatal arrhythmias but do not prevent death from heart failure progression.
- The safety profile of beta-blockers is comparable to placebo.
- Treatment with beta-blockers is recommended due to their benefits in reducing cardiac mortality.